• TRADE NAME: Kisqali (Novartis)
• INDICATIONS: Treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor)
• CLASS: CDK4/6 inhibitor
• HALF-LIFE: 30–55 hours

FDA APPROVAL DATE: 03/13/2017

Alfentanil, Amiodarone, Bepridil, Boceprevir, Chloroquine, Clarithromycin, Conivaptan, Cyclosporine, CYP3A4 substrates, Dihydroergotamine, Disopyramide, Ergotamine, Everolimus, Fentanyl, Grapefruit Juice, Halofantrine, Haloperidol, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Methadone, Midazolam, Moxifloxacin, Ondansetron, Pimozide, Procainamide, QT prolonging drugs, Quinidine, Rifampin, Ritonavir, Saquinavir, Sirolimus, Sotalol, Strong CYP3A4 inducers and inhibitors, Tacrolimus, Voriconazole

PREGNANCY CATEGORY: N/A
Can cause fetal harm